p1images / iStockphoto.com
The National Health Service (NHS) England is set to make record-breaking savings after negotiating deals with five manufacturers of low-cost biosimilar versions of the NHS's most expensive drug.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
NHS, National Health Service, biosimilars, biologics, cost savings, Adalimumab, AbbVie, patent expiry